CCM
BHVN

CAAS Capital Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

CAAS Capital Management’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-86,985
Closed -$5.95M – 1519
2021
Q1 		$5.95M Buy
+86,985
New +$7.04M 0.06% 319

Other funds holding BHVN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

CAAS Capital Management's BHVN Position: Q2 2021 in Review

CAAS Capital Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2021, closing a stake of 86,985 shares — an estimated $5.95M sold.

CAAS Capital Management first reported a position in BHVN in Q1 2021 and held it in 1 quarter. The position peaked at $5.95M in Q1 2021. 223 funds tracked by Wall St. Rank hold BHVN as of Q2 2021.

  • CAAS Capital Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2021 after selling out during the quarter.
  • CAAS Capital Management sold 86,985 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2021, an estimated $5.95M.
  • CAAS Capital Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2021 and held it in 1 quarter.
  • CAAS Capital Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $5.95M in Q1 2021.
  • 223 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2021.

Based on CAAS Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.